Table 1.
Characteristics of the MYHAT-NI cohort
| Characteristic | Overall N = 1111 |
Aβ-PET negative N = 831 |
Aβ-PET positive N = 281 |
p-value2 |
|---|---|---|---|---|
| Sex | 0.2 | |||
| Female | 60 (54%) | 42 (51%) | 18 (64%) | |
| Male | 51 (46%) | 41 (49%) | 10 (36%) | |
| Age | 76 (72, 80) | 75 (71, 79) | 79 (74, 83) | 0.052 |
| APOE | < 0.001 | |||
| Carrier | 18 (16%) | 6 (7.2%) | 12 (43%) | |
| Not carrier | 93 (84%) | 77 (93%) | 16 (57%) | |
| Education (years) | 12.0 (12.0, 16.0) | 12.0 (12.0, 16.0) | 12.5 (12.0, 15.0) | 0.7 |
| Self-identified racial identity | > 0.9 | |||
| Black/African American | 6 (5.4%) | 5 (6.0%) | 1 (3.6%) | |
| Non-Hispanic White | 105 (95%) | 78 (94%) | 27 (96%) | |
| CDR | 0.016 | |||
| 0 | 101 (91%) | 79 (95%) | 22 (79%) | |
| 0.5 | 10 (9.0%) | 4 (4.8%) | 6 (21%) | |
| Tau-PET Status | < 0.001 | |||
| Negative | 72 (65%) | 63 (76%) | 9 (32%) | |
| Positive | 39 (35%) | 20 (24%) | 19 (68%) | |
| Pittsburgh N Status | 0.10 | |||
| Negative | 41 (37%) | 27 (33%) | 14 (50%) | |
| Positive | 70 (63%) | 56 (67%) | 14 (50%) | |
| Mayo N Status | 0.5 | |||
| Negative | 78 (70%) | 57 (69%) | 21 (75%) | |
| Positive | 33 (30%) | 26 (31%) | 7 (25%) | |
| Lumipulse p-tau217 (pg/ml) | 0.13 (0.09, 0.19) | 0.12 (0.09, 0.16) | 0.23 (0.19, 0.40) | < 0.001 |
| (Missing) | 3 | 2 | 1 | |
| ALZPath p-tau217 (pg/ml) | 0.39 (0.27, 0.55) | 0.34 (0.22, 0.44) | 0.71 (0.56, 0.88) | < 0.001 |
| (Missing) | 1 | 1 | 0 | |
| NULISA p-tau217 (pg/ml) | 12.44 (12.09, 12.79) | 12.30 (12.03, 12.54) | 13.08 (12.76, 13.40) | < 0.001 |
| Johnson and Johnson p-tau217 (pg/ml) | 0.052 (0.037, 0.074) | 0.046 (0.035, 0.060) | 0.086 (0.067, 0.106) | < 0.001 |
| (Missing) | 18 | 13 | 5 |
1n (%), Median (Q1, Q3)
2Pearson’s Chi-squared test, Wilcoxon rank sum test, Fisher’s exact test